Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!

Not Applicable

Completed

• Conditions: Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity
• Interventions: Behavioral: Exercise intervention

• Registration Number: NCT01317576
• Lead Sponsor: Bram Brouwers

Brief Summary

Due to the western lifestyle, correlated with a high calorie intake and low physical activity, obesity is becoming a major health problem. All over the world obesity reaches epidemic proportions. Obesity is closely linked to type 2 diabetes, a multi-factorial disease that increases the presence of multiple health problems. Until now, exercise and dietary intervention seem to be the single most effective interventions to treat obesity and type 2 diabetes mellitus. In obesity and type 2 diabetes, not only fat accumulation in adipose tissue, but also fat accumulation in the peripheral tissues occurs. Fat accumulation in peripheral tissues has been associated with insulin resistance. Exercise seems to have a positive effect on the accumulation of fat in the peripheral tissue and on the insulin sensitivity in type 2 diabetic patients.

In this study we want to investigate if a prolonged exercise training program can lower the intrahepatic lipid content and can improve the metabolism of the liver in type 2 diabetic patients and patients with non-alcoholic fatty liver disease, and to examine if this leads to improvements in metabolic risk markers. To this end, we will include investigation of the effect of exercise on adipose tissue (inflammatory markers and adipocyte size) and skeletal muscle (ex vivo lipid metabolism) to incorporate the effect of exercise on liver, muscle and adipose tissue and to clarify the crosstalk between these tissues in the pathophysiology of type 2 diabetes.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-03
• Study First Submitted: 2011-03-16
• Study First Submitted QC: 2011-03-16
• Study First Posted: 2011-03-17
• Primary Completion: 2015-11
• Study Completion: 2015-11
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-27
• Last Update Posted: 2016-03-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 81

Inclusion Criteria

1. All subjects:

   • Male sex
   • Age 40-70 years
   • BMI 27-35 kg/m2
   • Stable dietary habits
   • Sedentary: No participation in any kind of sports for at least 2 years.

2. For diabetic patients only:

   • Must be on sulphonylurea or metformin therapy for at least 6 months with constant dose for at least 2 months, or on a dietary treatment for at least 6 months
   • Well-controlled diabetes: fasting plasma glucose concentration ≥ 7.0 mmol/l and < 10.0 mmol/l at the time of screening.

3. For subjects with non-alcoholic fatty liver disease:

   • Liver fat content ≥ 5,56%, based on the formula of Kotronen et al. and confirmed with MRS.
   • Fasting plasma glucose concentration must be < 7.0 mmol/l

4. For control subjects:

   • Liver fat content < 5,56%, based on the formula of Kotronen et al. and confirmed with MRS.
   • Normoglycemic according to the WHO criteria (OGTT)

Exclusion Criteria

1. All subjects:

   • Female sex
   • Unstable body weight (weight gain or loss > 3 kg in the past three months)
   • Participation in an intensive weight-loss program or in vigorous exercise program during the last year before the start of the study.
   • Active cardiovascular disease. (This will be determined by questionnaires and by screening on medication. Furthermore, all subjects will undergo a physical examination by a medical doctor).
   • Chronic renal dysfunction (creatinine > 2 increased (normal values: 64-104 µmol/l))
   • Use of Thiazolidines (glitazone/rosiglitazone/pioglitazone/troglitazone)
   • Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg
   • Haemoglobin < 7.5 mmol/l (anaemia)
   • Blood donor
   • Use of medication known to interfere with glucose homeostasis (i.e. corticosteroids), except for diabetic patients.
   • Use of anti-thrombotic medication
   • Claustrophobia and contra-indications for MRI
   • Abuse of alcohol(> 3 units (1unit = 10 gram ethanol) per day)
   • Abuse of drugs
   • Participation in another biomedical study within 1 month before the first screening visit

2. For diabetics:

   • Severe diabetes which requires application of insulin or patients with diabetes-related complications

3. For controls:

   • Liver disease or liver dysfunction (ALAT > 2.5 x increased)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Non-alcoholic fatty liver disease	Exercise intervention	This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
Healthy control	Exercise intervention	This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
Type 2 diabetes patients	Exercise intervention	This group will exist of patients that suffer from type 2 diabetes

Primary Outcome Measures

Name	Time	Method
Blood sampling to determine the concentration of cardiovascular risk factors in the blood before and after exercise	16 weeks
Magnetic resonance spectroscopy to measure the ATP and Pi concentrations in the liver	16 weeks
13C-methionine breath test to measure hepatic mitochondrial function	16 weeks	Subjects will drink a solution of 200ml H2O with 13C-Methionine. The following 2 hours, every 10 minutes a breath sample will be taken and analysed to measure the concentration of 13C in the exhaled breath.
Proton Magnetic resonance spectroscopy to measure the reduction in liver fat content after a training intervention	16 weeks
Euglycemic-hyperinsulinemic clamp for measurement of insulin sensitivity and metabolic flexibility	16 weeks	After taking fasting blood samples, a primed constant infusion of glucose is initiated. Plasma glucose levels are clamped at \~5 mmol/L by variable co-infusion of 20 % glucose. Every 5 minutes, blood is sampled for immediate determination of plasma glucose concentration. Glucose infusion rate is adjusted to obtain plasma glucose levels of \~5 mmol/L (euglycemia). A bolus of insulin is then infused. Before and during steady state, substrate oxidation is measured using an indirect calorimeter, which determines metabolic flexibility.

Secondary Outcome Measures

Name	Time	Method
Fat biopsy to measure adipose tissue inflammatory markers and adipocyte size before and after training intervention	16 weeks	A small amount of abdominal subcutaneous adipose tissue (\~1g) will be collected under local anaesthesia (2% lidocain) using needle biopsy (with the needle connected to a vacuum syringe). Inflammatory markers in the adipose tissue (e.g. IL-6, IL-8, IL-1b, PAI-1, TNFa, CD68, CD163, CD11b, MCP-1, leptin, adiponectin mRNA expression) and adipocyte size will be analysed
Muscle biopsy to measure muscle mitochondrial density, muscle mitochondrial function and muscle lipid metabolism	16 weeks	. After local anaesthesia (2.0% Xylocain without adrenaline), a 5-mm diameter side-cutting needle will be passed through a 7-mm skin incision, according to the protocol of the Medical Ethical committee of the Academic Hospital and University of Maastricht. The muscle biopsy will be used to measure ex vivo lipid metabolism, muscle mitochondrial density and muscle mitochondrial function.
Peripheral arterial tonometry to measure endothelial function, as a marker for cardiovascular risk.	16 weeks
Echography of the heart to measure diastolic dysfunction	16 weeks

Trial Locations

Locations (1)

Maastricht University; 🇳🇱 Maastricht, Limburg, Netherlands